Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Steven G DuBoisYael P Mosse

Abstract

Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in neuroblastoma. Irinotecan and temozolomide have activity in patients with advanced neuroblastoma. The goal of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinotecan and temozolomide in this population. Patients age 1 to 30 years with relapsed or refractory neuroblastoma were eligible. Patients received alisertib tablets at dose levels of 45, 60, and 80 mg/m(2) per day on days 1 to 7 along with irinotecan 50 mg/m(2) intravenously and temozolomide 100 mg/m(2) orally on days 1 to 5. Dose escalation of alisertib followed the rolling six design. Samples for pharmacokinetic and pharmacogenomic testing were obtained. Twenty-three patients enrolled, and 22 were eligible and evaluable for dose escalation. A total of 244 courses were administered. The MTD for alisertib was 60 mg/m(2), with mandatory myeloid growth factor support and cephalosporin prophylaxis for diarrhea. Thrombocytopenia and neutropenia of any grade were seen in the majority of courses (84% and 69%, respectively). Diarrhea in 55% of courses and nausea in 54% of courses were the most common nonhematologic toxicities. The overall response rate was 31.8%, ...Continue Reading

References

Jun 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·W A ColburnM Gibaldi
Apr 26, 1976·JAMA : the Journal of the American Medical Association·M Gibaldi, G Levy
May 3, 1976·JAMA : the Journal of the American Medical Association·M Gibaldi, G Levy
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N AdyL Manil
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G M BrodeurF Hedborg
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J O'Leary, F M Muggia
Apr 6, 1999·International Journal of Pediatric Otorhinolaryngology·U K Shah, R F Wetmore
Jun 16, 2007·Pediatric Blood & Cancer·Lars M WagnerWayne L Furman
Jun 26, 2007·Lancet·John M MarisSusan L Cohn
Oct 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa R BomgaarsSusan M Blaney
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey M SkolnikPeter C Adamson
Jan 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars M WagnerKatherine K Matthay
Aug 13, 2009·Molecular Cancer Therapeutics·Xiaoying ShangJed G Nuchtern
Aug 6, 2010·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Emily LipsitzPeter C Adamson
Sep 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leo MascarenhasDouglas S Hawkins
Dec 1, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rochelle BagatellSusan L Cohn
Jul 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andres CervantesJosep Tabernero
Jul 7, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·E Claire DeesJeffrey R Infante
Sep 19, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yael P MosséSusan M Blaney
Sep 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan W FriedbergSteven H Bernstein
Oct 12, 2013·Investigational New Drugs·Matthew P GoetzMatthew M Ames
Sep 2, 2014·Cancer Cell·William Clay GustafsonWilliam A Weiss

❮ Previous
Next ❯

Citations

Mar 22, 2016·Clinical and Experimental Pharmacology & Physiology·Cameron T DurlacherShu-Feng Zhou
Jul 15, 2016·Open Biology·Selena G BurgessRichard Bayliss
Aug 10, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Toulmonde
Nov 9, 2016·Critical Reviews in Oncology/hematology·Roberto LukschGian Paolo Tonini
Oct 18, 2016·Pediatric Blood & Cancer·Rajen J ModyArul M Chinnaiyan
Nov 12, 2016·Proceedings of the National Academy of Sciences of the United States of America·Mark W RichardsRichard Bayliss
Mar 4, 2017·Expert Opinion on Emerging Drugs·Pablo BerlangaVictoria Castel
Feb 2, 2017·Expert Review of Anticancer Therapy·Sarah B WhittlePeter E Zage
May 5, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R ParkDominique Valteau-Couanet
Mar 31, 2017·Genes·María Victoria Ruiz-PérezMarie Arsenian-Henriksson
Sep 15, 2017·Expert Opinion on Investigational Drugs·Loredana AmorosoMirco Ponzoni
Apr 11, 2018·Nature Reviews. Cancer·Jamie I FletcherMurray D Norris
Dec 12, 2018·International Journal of Cancer. Journal International Du Cancer·Lindi ChenDeborah A Tweddle
Nov 11, 2016·Nature Reviews. Disease Primers·Katherine K MatthayWilliam A Weiss
Oct 25, 2017·Expert Opinion on Orphan Drugs·Mark A ApplebaumSusan L Cohn
Sep 12, 2018·Children·Erin K Barr, Mark A Applebaum
Dec 7, 2018·Proceedings of the National Academy of Sciences of the United States of America·Eric W LakeNicholas M Levinson
Jul 13, 2017·Angewandte Chemie·James A H GilburtCharlotte A Dodson
Feb 2, 2019·Nature Reviews. Nephrology·Taryn Dora TregerSam Behjati
Jul 24, 2020·Oncology and Therapy·André Serra-Roma, Olga Shakhova
Jun 18, 2017·Biochemical Society Transactions·Richard BaylissMark W Richards
Mar 25, 2018·Cell and Tissue Research·Vanessa P Tolbert, Katherine K Matthay
Oct 18, 2018·Children·Emily G Greengard
Jan 30, 2018·Japanese Journal of Clinical Oncology·Akira NakagawaraMasanori Nishi
Jun 28, 2018·The Biochemical Journal·Nicholas Mark Levinson
Dec 3, 2017·In Vitro Cellular & Developmental Biology. Animal·Sandhya NoronhaMichael J Fay
Aug 11, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven G DuBoisAraz Marachelian
Apr 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sarah WangBrian D Crompton
Feb 22, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mari KogisoXiao-Nan Li
Feb 20, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yael P MosséBrenda J Weigel
Feb 13, 2021·Expert Opinion on Therapeutic Patents·Xue-Li Jing, Shi-Wu Chen
Aug 17, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sara M FedericoElizabeth Stewart
Feb 26, 2021·Frontiers in Oncology·Zhihui LiuCarol J Thiele
Jun 10, 2021·Neoplasia : an International Journal for Oncology Research·Joanna S YiW Clay Gustafson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.